TheraQuest's IND For Abuse Deterrent Strong Opioid (TQ-1015) Accepted By FDA

TheraQuest Biosciences, Inc. a
development stage pain management company announced that the U.S.
Food and Drug Administration (FDA) has accepted its Investigational New
Drug ("IND") application for TQ-1015, its abuse deterrent extended release
strong opioid. TQ-1015 is being developed using SECUREL(R), TheraQuest's
proprietary abuse deterrent technology.



Najib Babul, PharmD, Chief Executive Officer of TheraQuest stated,
"Sustained release opioids are the standard of care for the management of
chronic pain. Unfortunately, it is easy to defeat the sustained release
mechanim of such dosage forms, making them subject to drug diversion and
drug abuse. The TQ-1015 dosage form is highly tamper resistant, when
compared to OxyContin(R), thereby minimizing abuse by recreational drug
users and drug addicts."



About TQ-1015



TQ-1015 is a once-a-day extended release opioid analgesic for the
treatment of chronic pain. It has been developed using TheraQuest's
proprietary abuse deterrent extended release drug delivery system
(SECUREL(R)). TQ-1015 is significantly more potent than many current oral
therapies, including morphine and oxycodone. It shows robust efficacy in
various animal models of acute pain, inflammatory pain and neuropathic
pain. TQ-1015 will compete in the $8.3 billion U.S. opioid market.
What are Opioids?
For more information on what opioids are, and opioid-induced constipation (OIC), please see:
All About Opioids and Opioid-Induced Constipation (OIC)



About SECUREL(R)



Recent experience with extended release opioid pain relievers has shown
that intentional crushing or extraction of the active ingredient from the
dosage form by addicts and recreational drug users can destroy the
timed-release mechanism and result in a rapid surge of drug into the
bloodstream. Serious side-effects and death have been reported from such
misuse.



SECUREL(R) is TheraQuest's proprietary abuse deterrent extended release
technology for oral abusable drugs. SECUREL(R) dosage forms cannot be
easily crushed for inhalation or to obtain rapid euphoria from high blood
levels when swallowed. It is also exceedingly difficult for I.V. abusers to
extract the active drug from the dosage form using common solvents,
including alcohol.



About TheraQuest



TheraQuest Biosciences, Inc. (theraquestinc) is a
private, development-stage pain management company building a diversified
portfolio of pharmaceutical products to address a critical area of unmet
medical need. Despite their limitations, current treatments for acute and
chronic pain yield worldwide sales in excess of $30 billion. The TheraQuest
team has contributed to the development of numerous analgesics approved in
the U.S. over the past 20 years. TheraQuest's strategy is to use its
expertise to identify, develop and commercialize product candidates with
strong market potential that have lower development costs and reduced
regulatory risk than new chemical entities. TheraQuest is headquartered in
Blue Bell, Pennsylvania.



TheraQuest is funded in part by BioAdvance, the Biotechnology
Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology
Partners of Southeastern Pennsylvania.



SECUREL(R) and OxyContin(R) are registered trademarks of TheraQuest
Biosciences, Inc., and Purdue Pharma LP., respectively.


TheraQuest Biosciences, Inc.

theraquestinc



View drug information on Oxycodone and Aspirin.